View Older Stories

Sep 30, 2026 08:30AM Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Can

Sep 30, 2026 08:06AM Candel Therapeutics reports immune data for prostate cancer drug at ASTRO

Sep 30, 2026 08:05AM Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026

Sep 10, 2026 08:05AM Candel Therapeutics adds regulatory veteran to its board

Sep 10, 2026 08:05AM Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors

Sep 1, 2026 04:05PM Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 26, 2026 08:05AM Candel Therapeutics to Present at September Investor Conferences

Aug 13, 2026 08:05AM Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Aug 3, 2026 04:05PM Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 3, 2026 08:05AM Candel Therapeutics to present prostate cancer data at ASTRO 2026

Aug 3, 2026 08:05AM Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026

Jul 29, 2026 08:05AM Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston

Jul 8, 2026 04:05PM Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2026 04:05PM Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 30, 2026 08:05AM Candel Therapeutics launches phase 3 lung cancer trial for CAN-2409

Jun 30, 2026 08:05AM Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response

Jun 25, 2026 08:05AM Candel Therapeutics names Mark Sims as chief commercial officer

Jun 25, 2026 08:05AM Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

Jun 2, 2026 08:05AM Candel publishes phase 3 prostate cancer trial data in Lancet Oncology

Jun 2, 2026 08:05AM Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Loca

Jun 1, 2026 04:05PM Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 15, 2026 04:05PM Candel Therapeutics reports extended clinical benefits in phase 3 prostate cancer trial

May 15, 2026 04:05PM Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonge

May 14, 2026 08:05AM Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 13, 2026 08:05AM Candel Therapeutics to Present at Upcoming Investor Conferences

May 4, 2026 08:05AM Candel Therapeutics schedules call on prostate cancer trial data

May 4, 2026 08:05AM Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Asso

May 1, 2026 04:05PM Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 29, 2026 08:05AM Candel Therapeutics partners with EVERSANA for drug commercialization

Apr 29, 2026 08:05AM Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer

Apr 2, 2026 04:05PM Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 17, 2026 08:05AM Candel reports extended survival in lung cancer trial

Mar 17, 2026 08:05AM Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoin

Mar 12, 2026 08:05AM Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Mar 9, 2026 08:05AM Candel Therapeutics to present prostate cancer trial data at AUA meeting

Mar 9, 2026 08:05AM Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annu

Mar 2, 2026 04:05PM Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 24, 2026 08:05AM Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston

Feb 19, 2026 09:40PM Candel Therapeutics prices $100 million public offering at $5.45 per share

Feb 19, 2026 09:40PM Candel Therapeutics Announces Pricing of Public Offering

Feb 19, 2026 04:05PM Candel Therapeutics launches $100 million public offering

Feb 19, 2026 04:05PM Candel Therapeutics Announces Proposed $100 Million Public Offering

Feb 19, 2026 04:02PM Candel Therapeutics secures $100M royalty funding deal with RTW

Feb 19, 2026 04:01PM Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

Feb 11, 2026 08:05AM Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit

Feb 2, 2026 04:05PM Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 17, 2025 04:05PM Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

Nov 17, 2025 04:05PM Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

Nov 13, 2025 08:25AM Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Nov 4, 2025 09:00AM Candel Therapeutics to present phase 3 prostate cancer trial results at SITC

View Older Stories